Background
==========

Hippo signalling is a tumour suppressor cascade highly conserved from yeast to man \[[@B1]\]. In mammals, Hippo signalling is deregulated in various cancers; hence, mammalian Hippo signalling has gained much attention over the past years \[[@B2]\]. In a nutshell, the canonical Hippo pathway functions as follows: activated MST1/2 kinases (mammalian Ste20-like serine/threonine kinase 1/2) phosphorylate hMOB1 (human Mps one binder 1) and LATS1/2 (large tumour suppressor serine/threonine kinase 1/2), resulting in the formation of an active hMOB1-LATS complex that phosphorylates the protooncogenes YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif), which finally leads to the accumulation of inactive cytoplasmic YAP/TAZ \[[@B3]\].

YAP is overexpressed in various human cancers \[[@B4],[@B5]\], supporting a role for it as a proto-oncogene. In breast cancer, however, gain or loss of YAP expression has been reported \[[@B6]-[@B9]\], suggesting that YAP might have oncogenic and tumour suppressive functions dependent on the breast cancer subtype. TAZ is overexpressed in breast cancer \[[@B10],[@B11]\], but a recent report \[[@B12]\] suggests also a tumour suppressive role for TAZ. Therefore, the roles of YAP/TAZ-Hippo signalling in breast cancer are debatable. Considering that metastases at distant sites, and not the primary breast tumour, are the main cause of death, we must further consider YAP/TAZ functions in metastasis, as highlighted by a recent report by Ma and colleagues \[[@B13]\].

The articles
============

To uncover novel factors involved in the initiation/progression of tumours, Lippman and colleagues \[[@B12]\] screened *in vivo*the entire human genome by RNA interference, thereby identifying LIFR as a novel tumour suppressor. Silencing of LIFR was sufficient to transform normal mammary cells, and reciprocally, LIFR over-expression in breast cancer cells suppressed tumour growth \[[@B12]\], suggesting that LIFR is a clinically important breast tumour suppressor. However, Iorns and colleagues \[[@B12]\] did not define how LIFR functions as a tumour suppressor.

In parallel, Ma and co-workers discovered a role for LIFR as a novel breast cancer metastasis suppressor \[[@B13]\]. In full agreement with Iorns and colleagues \[[@B12]\], they also found that LIFR is downregulated in breast cancer \[[@B13]\], but controversially reported that LIFR silencing did not affect primary tumour growth \[[@B13]\]. However, over-expression of LIFR in metastatic breast cancer cell lines dramatically reduced metastases formation \[[@B13]\]. Furthermore, Ma and colleagues investigated the mechanisms downstream of LIFR. Based on a recent report \[[@B14]\] linking LIF (the ligand for LIFR) to the regulation of YAP, they examined the role of LIFR in YAP-Hippo signalling. Unlike in embryonic stem cells \[[@B14]\], addition of LIF resulted in increased YAP phosphorylation in breast cancer cell lines, thereby resulting in the inactivation of YAP \[[@B13]\]. Since phosphorylation of MST/LATS was increased upon LIFR overexpression \[[@B13]\], it is possible that the effect on YAP is driven by canonical Hippo signalling. Moreover, they provided evidence suggesting that LIFR signals to MST/LATS via Scribble \[[@B13]\], an adaptor that can link MST/LATS/YAP/TAZ complexes \[[@B11]\].

The viewpoint
=============

Two recent reports highlight LIFR as a novel player in breast cancer. The work by Iorns and colleagues \[[@B12]\] defines LIFR as a breast tumour suppressor, while Ma and co-workers \[[@B13]\] define LIFR as a breast cancer metastasis suppressor. Current evidence strongly suggests that LIFR functions by inhibiting YAP \[[@B13]\]. This novel role for YAP in breast cancer metastasis is supported by a recent paper from the Hynes laboratory \[[@B15]\], but the involvement of canonical Hippo signalling is not so evident. They show that LIFR overexpression correlates with increased LATS1 phosphorylation, while YAP(S112A) drives metastases despite LIFR overexpression \[[@B13]\]. This suggests that LIFR triggers YAP phosphorylation by activating LATS1. However, given that YAP phosphorylation appears to be independent of LATS1/2 in other cancer settings \[[@B16]\], it will be important to confirm the identity of the kinase(s) targeting YAP in these settings before we can make final conclusions.

Considering that TAZ-Hippo signalling is already implicated in breast cancer \[[@B10],[@B11]\], it is likely that LIFR also functions upstream of TAZ. In particular, it will be interesting to determine whether the recently reported role for TAZ in breast cancer metastasis \[[@B17]\] is controlled by LIFR. However, Iorns and colleagues identified TAZ (WWTR1) as a potential breast tumour suppressor in their screen \[[@B12]\]. At first glance, these observations do not seem to make sense, but as already speculated for YAP \[[@B4],[@B6]-[@B9]\], TAZ might have oncogenic and tumour suppressive functions dependent on the breast cancer subtype or progression stage, a phenomenon already reported for other factors in different cancer types \[[@B18]\]. Since increased YAP/TAZ levels correlate with taxol resistance \[[@B7],[@B19]\], YAP/TAZ have been considered as targets/biomarkers in breast cancer. Based on the work by the Ma and Lippman laboratories \[[@B12],[@B13]\], however, LIFR activation appears to be the more attractive clinical target for the treatment of breast cancer, since the roles of YAP/TAZ-Hippo signalling in breast cancer subtypes are yet to be defined in more detail.

Abbreviations
=============

LIF: leukemia inhibitory factor; LIFR: leukemia inhibitory factor receptor.
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